Core Viewpoint - Curis, Inc. has announced a definitive agreement for a registered direct offering and concurrent private placement, aiming to raise approximately $7.0 million to support its research and development efforts [1][2]. Group 1: Offering Details - Curis will issue 1,538,460 shares of common stock at a market price, along with unregistered pre-funded warrants and common warrants [1]. - The pre-funded warrants will allow investors to purchase an additional 1,538,461 shares at an exercise price of $0.01, while common warrants will allow for the purchase of 3,076,921 shares at an exercise price of $2.15 [1]. - The combined purchase price for one share and the associated common warrant is $2.275, and for one pre-funded warrant and the associated common warrant is $2.265 [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for research, development, working capital, and other general corporate purposes [2]. Group 3: Closing and Agents - The registered direct offering and concurrent private placement are expected to close on or about July 3, 2025, pending customary closing conditions [2]. - Laidlaw & Company (U.K.) Ltd. and Jones are acting as placement agents for the offerings [3]. Group 4: Regulatory Information - The shares are being offered under a shelf registration statement filed with the SEC, and a prospectus supplement will be available on the SEC's website [4]. - The unregistered warrants are being offered under an exemption from registration requirements, and Curis will file a resale registration statement with the SEC for the underlying shares [5]. Group 5: Company Overview - Curis is focused on developing emavusertib, an orally available IRAK4 inhibitor, currently in various clinical studies for treating relapsed/refractory cancers [7][8]. - Emavusertib has received Orphan Drug Designation from the FDA for multiple cancer treatments [8].